# Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage.

Study · id `cardio:ct-nct07583147` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07583147](<https://clinicaltrials.gov/study/NCT07583147>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07583147

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 117 participants.

## Technical summary

Registry record NCT07583147. Allocation not applicable; no masking; primary purpose basic science. Start 2026-06 (anticipated); primary completion 2029-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose basic science
- Phase: Phase 2
- Enrolled: 117 participants (planned count; ClinicalTrials.gov record NCT07583147, source copy `cardio:ctgov-nct07583147-2026-05-13`, retrieved 2026-10-31)
- Planned start: 2026-06 (anticipated) (ClinicalTrials.gov record NCT07583147, source copy `cardio:ctgov-nct07583147-2026-05-13`, retrieved 2026-10-31)
- Primary completion: 2029-09 (anticipated) (ClinicalTrials.gov record NCT07583147, source copy `cardio:ctgov-nct07583147-2026-05-13`, retrieved 2026-10-31)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07583147, source copy `cardio:ctgov-nct07583147-2026-05-13`, retrieved 2026-10-31)
- Countries: France (ClinicalTrials.gov record NCT07583147, source copy `cardio:ctgov-nct07583147-2026-05-13`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07583147-2026-05-13`, retrieved 2026-10-31)

## The registry's words

- Brief title: Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage.
- Acronym: INFINITE
- Condition: Intracerebral Hemorrhage
- Intervention (Drug): TEP with 18F-DPA-714 injection
- Lead sponsor: University Hospital, Toulouse
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Bleeding in the brain (intracerebral hemorrhage) (`cardio:intracerebral-hemorrhage`)
- Registry lists this organization as the lead sponsor: University Hospital, Toulouse (`cardio:org-university-hospital-toulouse`)

## Provenance

Content hash: e64307921b5cef18d0c8c2602be357351458ed7890100ce5a901365660303b99
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
